文献速递冠心病

2016 NICE高敏肌钙蛋白排除策略评估

Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy.
PubMed 文献 · Heart · 2017-09-01

该研究汇总6项前瞻性研究,评估2016 NICE指南中高敏肌钙蛋白联合TIMI评分排除策略。结果显示TIMI=0联合hs-cTnT或hs-cTnI敏感性分别为99.5%和98.9%,可将17.9%-21.0%患者归为低危,支持NICE策略且临床TIMI阈值建议为0。

要点

  • TIMI=0联合hs-cTnT敏感性99.5%,联合hs-cTnI敏感性98.9%。
  • TIMI=0时分别有17.9%和21.0%患者被归为低危。
  • TIMI≤2时两种检测敏感性均低于98%,不宜作为阈值。

核心结论

  • 研究结果支持2016 NICE指南提出的排除策略,临床使用的TIMI评分阈值建议为0。

研究设计与样本

  • 汇总分析6项前瞻性研究,纳入澳大利亚、新西兰和英国急诊就诊的胸痛且心电图非缺血性改变的成年患者。

主要发现

  • hs-cTnT组3159例中376例(11.9%)发生30天主要不良心脏事件,hs-cTnI组4532例中445例(9.8%)发生。
  • TIMI=0联合hs-cTnT敏感性99.5%(95%CI 98.1% to 99.9%),联合hs-cTnI敏感性98.9%(95%CI 97.4% to 99.6%)。
  • TIMI=0时分别有17.9%和21.0%患者被归为低危。
  • TIMI≤1联合hs-cTnT敏感性98.9%(95%CI 97.3% to 99.7%),联合hs-cTnI敏感性98.4%(95%CI 96.8% to 99.4%)。
  • TIMI≤2时两种检测的合并敏感性均低于98%。

关键数值与推荐

  • TIMI=0联合hs-cTnT:敏感性99.5%(95%CI 98.1% to 99.9%),低危比例17.9%。
  • TIMI=0联合hs-cTnI:敏感性98.9%(95%CI 97.4% to 99.6%),低危比例21.0%。
  • TIMI≤1联合hs-cTnT:敏感性98.9%(95%CI 97.3% to 99.7%),低危比例28.1%。
  • TIMI≤1联合hs-cTnI:敏感性98.4%(95%CI 96.8% to 99.4%),低危比例35.7%。

临床怎么用

  • 对急诊胸痛且心电图非缺血性改变的患者,可采用TIMI=0联合高敏肌钙蛋白作为排除策略。
  • 该策略可将约18%-21%的患者归为低危,适合早期出院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to evaluate the limit of detection of high-sensitivity troponin (hs-cTn) and Thrombolysis In Myocardial Infarction (TIMI) score combination rule-out strategy suggested within the 2016 National Institute for Health and Care Excellence (NICE) Chest Pain of Recent Onset guidelines and establish the optimal TIMI score threshold for clinical use. METHODS: A pooled analysis of adult patients presenting to the emergency department with chest pain and a non-ischaemic ECG, recruited into six prospective studies, from Australia, New Zealand and the UK. We evaluated the sensitivity of TIMI score thresholds from 0 to 2 alongside hs-cTnT or hs-cTnI for the primary outcome of major adverse cardiac events within 30 days. RESULTS: Data were available for 3159 patients for hs-cTnT and 4532 for hs-cTnI, of these 376 (11.9%) and 445 (9.8%) had major adverse cardiac events, respectively. Using a TIMI score of 0, the sensitivity for the primary outcome was 99.5% (95% CI 98.1% to 99.9%) alongside hs-cTnT and 98.9% (97.4% to 99.6%)%) alongside hs-cTnI, identifying 17.9% and 21.0% of patients as low risk, respectively. For a TIMI score ≤1 sensitivity was 98.9% (97.3% to 99.7%)%) alongside hs-cTnT and 98.4% (96.8% to 99.4%)%) alongside hs-cTnI, identifying 28.1% and 35.7% as low risk, respectively. For TIMI≤2, meta-sensitivity was <98% with either assay. CONCLUSIONS: Our findings support the rule-out strategy suggested by NICE. The TIMI score threshold suggested for clinical use is 0. The proportion of patients identified as low risk (18%-21%) and suitable for early discharge using this threshold may be sufficient to encourage change of practice. TRIAL REGISTRATION NUMBERS: ADAPT observational study/IMPACT intervention trial ACTRN12611001069943.ADAPT-ADP randomised controlled trial ACTRN12610000766011. EDACS-ADP randomised controlled trial ACTRN12613000745741. TRUST observational study ISRCTN no. 21109279.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Carlton EW, Pickering JW, Greenslade J, et al. Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy. Heart. 2017. PMID: 28864718. doi:10.1136/heartjnl-2017-311983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。